Why the study?
Does the Impella 2.5 left ventricular assist device improve clinical status and ejection fraction in a patient with cardiogenic shock secondary to takotsubo cardiomyopathy?
Does the Impella 2.5 left ventricular assist device improve clinical status and ejection fraction in a patient with cardiogenic shock secondary to takotsubo cardiomyopathy?
The Impella 2.5 device may serve as an effective mechanical circulatory support strategy for patients with cardiogenic shock secondary to takotsubo cardiomyopathy who are deteriorating on medical therapy.
Answers are grounded in this paper and cite their sources.
May support Impella rescue in refractory takotsubo shock; leaves open efficacy in prospective studies.
We report a case of cardiogenic shock, believed to be secondary to stress-induced cardiomyopathy, managed by an Impella 2.5 assist device. Apical ballooning pattern was evident on left ventriculogram with no significant coronary artery disease on coronary angiography. Cardiogenic shock was initially managed medically with inotropes and vasopressors, but because the patient was clinically deteriorating, an Impella 2.5 left ventricular assist device was implanted. Remarkable recovery occurred within 48 h of implantation with significant increase in ejection fraction and only minimal residual apical hypokinesis observed on repeat ventriculogram.
No takes yet. Share an insight, caveat, or question.
Rashed et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: